Initial strategies for the blockade of Dkk-1 began with antibodies, and these showed promise in myeloma models [20] and in humans [44], but antibodies must be given at large doses given that Dkk-1 levels in humans can reach hundreds of ng mL−1 [10, 12]. The gene discussed is DKK1; the disease is plasma cell myeloma.